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Abstract
Purpose Current positron emission tomography (PET)
radioligands for detection of Aβ amyloid in Alzheimer’s
disease (AD) are not ideal for quantification. To improve
the signal to noise ratio we have developed the radioligand
[
11C]AZD2184 and report here the first clinical evaluation.
Methods EightADpatientsandfouryounger control subjects
underwent 93-min PET measurements with [
11C]AZD2184.
A ratio approach using the cerebellum as reference region
was applied to determine binding parameters.
Results Brain uptake of [
11C]AZD2184 peaked within 1 min
at 3–4% of injected radioactivity. AD patients had high
radioactivity in cortical regions while controls had uniformly
low radioactivity uptake. Specific binding peaked within
30 min at which time standardized uptake value ratios
(SUVR) ranged between 1.19 and 2.57.
Conclusion [
11C]AZD2184 is a promising radioligand for
detailed mapping of Aβ amyloid depositions in Alzheimer’s
disease, due to low non-specific binding, high signal to
background ratio and reversible binding as evident from early
peak equilibrium.
Keywords Alzheimer’sdisease.Imaging.Amyloid.
Biomarker.PET.MRI
Introduction
Alzheimer’s disease (AD) is a major cause of dementia
estimated to affect more than 30 million people worldwide
[1]. While clinical diagnosis is based on symptoms, definite
AD diagnosis is based on post-mortem identification of
extracellular β-amyloid (Aβ) plaques and intraneuronal
neurofibrillary tangles. Formation of neuritic plaques by
Aβ deposits is thought to play a major role in the
pathophysiology of AD, and several therapeutic agents
intended to remove or prevent the build-up of amyloid
deposits are currently in clinical development. Recent
development of positron emission tomography (PET)
radioligands for detection of amyloid in patients has
provided a new potential for diagnosis of AD during
lifetime, ideally before the onset of clinical symptoms. It is
also of interest to explore rate and distribution pattern of
amyloid formation in relation to clinical progression.
However, the first generation of radioligands for PET,
including the Pittsburgh compound B ([
11C]PIB) [2], are
not ideal for quantification due to low signal to noise ratio,
high non-specific binding or unfavourable kinetics [3].
We have recently developed the new putative radioligand,
5-(6-{[tert-butyl(dimethyl)silyl]oxy}-1,3-benzothiazol-2-yl)
pyridin-2-amine (AZD2184), which has high affinity in vitro
for amyloid fibrils [dissociation constant (Kd) 8.4±1.0 nM]
[4]. Autoradiography on cortical brain sections from APP/
PS1 mice and AD patients has shown that [
3H]AZD2184 has
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3H]
PIB, particularly because of lower non-specific binding [4].
Preclinical characterization thus suggests that
11C-labelled
AZD2184 may provide higher sensitivity for Aβ amyloid
than the reference radioligand [
11C]PIB. The aim of this first
PET study with [
11C]AZD2184 in AD patients and control
subjects was to evaluate the suitability of this radioligand for
detection and quantification of brain Aβ amyloid. This
report is a descriptive summary of the findings.
Materials and methods
The study was conducted at the PET Centre at Karolinska
University Hospital Solna, with AD subjects recruited from
the Karolinska University Hospital Memory Clinic at Hud-
dinge, Sweden. The study was approved by the Regional
Ethics Committee in Stockholm, Sweden and was performed
in accordance with the Declaration of Helsinki and Interna-
tional Conference on Harmonization/Good Clinical Practice
guidelines. Written informed consent was obtained from all
subjects and caregivers before enrolment.
Subjects
Eight patients fulfilling DSM-IV AD criteria (four female,
mean age: 62.6 years, range: 55–76) were recruited. AD
was characterized according to a routine clinical protocol
including the Mini-Mental State Examination (MMSE),
brain imaging (MRI or CT), neuropsychological assess-
ments and CSF analyses. Four control subjects (male, mean
age: 28.8 years, range: 23–36) were recruited. To allow
detailed examination of non-specific binding (i.e. the
background), young control subjects were chosen to
minimize the likelihood of amyloid pathology.
Properties and radiosynthesis of [
11C]AZD2184
[
11C]AZD2184 was produced according to Andersson et al.
[5]. [
11C]methane was produced in target via the
14N(p,α)
11C
reaction on nitrogen with 10% hydrogen, using 16.4 MeV
protons (GEMS PET trace cyclotron). [
11C]methane was
passed through a heated column containing I2 to produce
[
11C]methyl iodide via a radical reaction [6]. [
11C]methyl
iodide was trapped in a vessel containing 2.5 mg of the
precursor, 5-(6-(tert-butyldimethyl-silyloxy)benzo[d]thiazol-
2-yl)pyridin-2-amine), and potassium hydroxide (10 mg) in
dimethyl sulphoxide (DMSO) (300 µl). Heating at 125°C for
5 min was performed followed by deprotection with water
(200 µl) at room temperature for 2 min to yield [
11C]2184.
[
11C]2184 was purified by reversed phase HPLC. The
fraction that contained the product was evaporated to
dryness and the residue re-dissolved into 6 ml sterile
physiological phosphate buffer (pH=7.4). After sterile
filtration, the formulated product solution was sterile and
free from pyrogens.
Imaging procedures and analyses
MRI was performed on a 1.5-T Siemens Avanto scanner.
The PET system ECAT EXACT HR (resolution 3.8 mm
full-width at half-maximum) was run in three-dimensional
mode, using individually made plaster helmets for head
fixation.
In each PET measurement radioactivity was recorded for
93 min following intravenous bolus injection of radio-
ligand. Reconstructed, attenuation- and decay-corrected
PET data were displayed as 47 transaxial slices in a 128×
128 matrix [7]. Arterial blood samples were drawn for
determination of radioactivity in whole blood and plasma as
well as for analysis of unchanged radioligand in plasma [7].
The first four AD subjects were examined once, while the
other subjects were examined twice during the same day in a
test-retest approachwithatleast 2.5 h between measurements.
The injected radioactivity and specific radioactivity were
Table 1 Regional standardized uptake value ratios
Region AD CS
ACG 2.28 (15.2) 1.06 (1.5)
CAU 1.95 (22.0) 0.88 (3.3)
CER - -
SWM 1.50 (17.6) 1.33 (7.2)
DLPC 2.27 (16.4) 1.05 (2.2)
DMPC 2.37 (16.9) 1.02 (3.1)
HIP 1.31 (17.3) 1.05 (11.5)
LTC 2.23 (15.3) 1.06 (1.6)
MTC 1.54 (15.1) 1.07 (4.1)
OCC 1.74 (18.8) 1.15 (2.4)
OFC 2.42 (14.3) 1.05 (1.1)
PAR 2.12 (15.6) 0.99 (4.4)
PONS 1.19 (16.3) 1.12 (5.9)
PCG 2.57 (16.5) 1.07 (9.2)
SMC 1.59 (17.0) 0.97 (9.0)
PUT 1.88 (19.3) 1.07 (5.1)
WB 1.73 (13.1) 1.09 (4.8)
Values shown are mean and coefficient of variation (%), n=8 for AD,
n=4 for CS
ACG anterior cingulate gyrus, CAU caudate nucleus, CER cerebellum,
SWM subcortical white matter, DLPC dorsolateral prefrontal cortex,
DMPC dorsomedial prefrontal cortex, HIP hippocampus, LTC lateral
temporal cortex, MTC medial temporal cortex, OCC occipital cortex,
OFC orbitofrontal cortex, PAR parietal cortex, PONS pons, PCG
posterior cingulate gyrus, SMC sensorimotor cortex (primary), PUT
putamen, WB whole brain
1860 Eur J Nucl Med Mol Imaging (2009) 36:1859–1863similar between AD patients (323±10 MBq and 14,866±
7,533 Ci/mmol, respectively) and control subjects (305±
46 MBq and 29,083±13,896 Ci/mmol, respectively). Injected
radioligand mass ranged from 0.04 to 0.48 μg. The MR
images were reoriented in a standardized manner and used to
segment the brain into grey and white matter. Regions of
interest (ROIs) were drawn manually on the individual MR
images for 17 cortical and subcortical structures (Table 1).
The cortical ROIs were intersected with the grey matter
segment image to only keep voxels within the grey
matter. The PET images were coregistered to the
reoriented T1-weighted MR images and time-activity
curves (TACs) were extracted for the defined ROIs. No
partial volume effect correction was applied, since such
correction might overestimate uptake curves and specific
b i n d i n gi nA Dp a t i e n t sw i t ha t r o p h y .
The cerebellum was used as a reference region since this
region is devoid of amyloid deposits [2, 8]. Specific
binding was defined as the difference of radioactivity
between other ROIs and the cerebellum. The standardized
uptake value ratio (SUVR) has been proposed as an index
for Aβ amyloid binding [8]. The SUVR was calculated for
the approximate time of peak equilibrium (24–30 min).
Results
All subjects completed the study according to the protocol.
The patients suffered from AD at a mild to moderate stage
(median MMSE: 20, range: 16–26); seven were treated
with choline esterase inhibitors. In all AD patients the
summation PET images showed a high uptake of [
11C]
AZD2184 in regions known to contain Aβ depositions,
whereas uptake was low in the cerebellum (Fig. 1). In
control subjects radioligand uptake was low and homoge-
neous. As evaluated from visual inspection, there was no
difference in the normalized whole blood and the
metabolite-corrected input function between AD patients
and healthy controls (Fig. 2). Radioligand metabolism was
fast with less than 20% of [
11C]AZD2184 remaining unchanged
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Fig. 1 Summation PET images
showing uptake between 7 and
90 min in SUV units
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Fig. 2 Whole-brain relative uptake over time as measured by
percentage of injected radioactivity that enters the brain. Insert shows
the radioactivity in whole blood and the metabolite-corrected input
function in AD patients and control subjects (mean±SD, n=8 for AD,
n=4 for CS)
Eur J Nucl Med Mol Imaging (2009) 36:1859–1863 1861in plasma 20 min after administration. All metabolites were
more hydrophilic than the mother compound.
The peak of whole-brain uptake of [
11C]AZD2184
appeared within 1 min and was between 3 and 4% of the
injected radioactivity (Fig. 2). After the initial peak, there
was a rapid washout of radioactivity in all subjects. TACs
from AD patients showed markedly higher radioactivity in
the target regions than in the cerebellum, whereas the TACs
from control subjects were all on the same level. The
cerebellar TACs were higher for AD patients than for the CS
group in the early times of the experiment. However, from
40 min after injection the two curves were at a similar level
(Fig. 3a).
Theratioofregionalradioactivitytothatofcerebellumwas
stablefrom30minafterinjectiontotheendofdataacquisition
(Fig. 3c). The difference between the TACs for the amyloid-
rich ROIs and that of the cerebellum gives an approximation
of specific binding over time (Fig. 3d). All such curves from
the AD patients peak at 20–30 min after injection and
decline in the rest of the experiment. The curves from
healthy volunteers were essentially flat as expected from the
inspection of the raw regional TACs (Fig. 3d).
The SUVR were substantially higher for AD patients than
for control subjects in regions expected to contain Aβ
depositions (Fig. 3c, Fig. 4). The control group had SUVR
close to one in all regions and subjects (Fig. 4, Table 1). In a
preliminary analysis (data not shown) the test-retest variabil-
ity was on average 4% across cortical regions in all subjects.
Discussion
The aim of this first clinical study was to evaluate the
suitability of [
11C]AZD2184 for detection of Aβ
amyloid depositions in AD patients. Radioactivity was
high in regions expected to contain Aβ amyloid and
low in the cerebellum, a reference region presumably
devoid of amyloid deposits. The obvious inter-subject
variability is consistent with expected differences in
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Fig. 3 Standardized uptake
value over time for a cerebellum
and b posterior cinguli.
c SUVR over time. For clarity,
the ratio of one is shown
depicting no specific binding.
d Approximated specific
binding (i.e. radioactivity in ROI
minus cerebellum) over time in
posterior cingulate. Note the
early peak of specific binding
around 20 min (mean±SD,
n=8 for AD, n=4 for CS)
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Fig. 4 Standardized uptake ratio values (SUVR) for four different
regions calculated using peak SUVR. ACG anterior cingulate gyrus,
LTC lateral temporal cortex, PCG posterior cingulate gyrus, WB white
matter
1862 Eur J Nucl Med Mol Imaging (2009) 36:1859–1863plaque load and studies with other PET radioligands for
amyloid [2]. In contrast, there was homogeneously low
radioactivity across all brain regions in young controls
subjects, likely to be devoid of amyloid depositions in
brain. The PET results are consistent with preclinical
demonstration of low background binding of [
3H]
AZD2184 [4]. The low background radioactivity is
advantageous for detection of low levels of amyloid
depositions such as before clinical onset of AD.
Maximal contrast (signal to noise) appeared already
after about 30 min, and specific binding peaked at about
20 min. This indicates that the kinetics of [
11C]
AZD2184 binding are fast and reversible and may allow
adequate quantification within 30 min after injection. The
rapid washout may partly be related to the rapid
metabolism of [11C]2184 in plasma. Short acquisition
time improves patient compliance and allows for multi-
tracer PET measurements.
The early high brain uptake of radioactivity (Fig. 2)
demonstrates that the radioligand readily passes the blood-
brain barrier. Preclinical comparison between [
3H]
AZD2184 and [
3H]PIB in rodents and post-mortem AD
brains supports the view that AZD2184 has advantageous
contrast due to lower non-specific background binding [4].
Moreover, PET studies on [
11C]PIB have demonstrated
slow kinetics and the need for long acquisition times for
reliable quantification [9].
The current assessment does not include full kinetic
analysis, which will be the subject of a more detailed
report. The observation of high contrast images with
low non-specific binding and the early peak of specific
binding is, however, sufficient to conclude that [
11C]
AZD2184 is a promising radioligand for early detection
and quantification of Aβ amyloid depositions in the living
human brain using short scanning protocols.
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